(Q35873789)

English

Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics

scientific article published on 29 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

0 references

1 reference

25 January 2021

Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

0 references

1 reference

25 January 2021

systematic review

1 reference

based on heuristic

inferred from title

relapse prevention

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

T Kishimoto

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

V Agarwal

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

T Kishi

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

S Leucht

4

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

J M Kane

5

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

C U Correll

6

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

29 November 2011

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1 January 2013

1 reference

25 January 2021

Molecular Psychiatry

2 references

Europe PubMed Central

PMC publication ID

10 August 2017

25 January 2021

18

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

53-66

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

https://scigraph.springernature.com/pub.10.1038/mp.2011.143

0 references

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Past and present progress in the pharmacologic treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Olanzapine and haloperidol in first episode psychosis: two-year data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

27 July 2018

Evidence-based pharmacotherapy of schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3320691

24 September 2018

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.143

21 January 2018

Antipsychotic drugs and obesity

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.143

21 January 2018

Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models

1 reference

https://pubmed.ncbi.nlm.nih.gov/22124274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22124274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine in tardive dyskinesia: observations from human and animal model studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/22124274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

1 reference

https://pubmed.ncbi.nlm.nih.gov/22124274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22124274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

1 reference

https://pubmed.ncbi.nlm.nih.gov/22124274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22124274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacotherapy of first-episode schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22124274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.143

7 January 2021

based on heuristic

inferred from DOI database lookup

A premenopausal woman with virilization secondary to an ovarian Leydig cell tumor

1 reference

https://api.crossref.org/works/10.1038%2FMP.2011.143

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MP.2011.143

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35873789&oldid=2161266116"